MRSA Testing Market Size, Share and Global Trend By Test Type (Molecular Diagnostic Tests, Immunodiagnostic Tests), By End User (Hospitals, Diagnostic & Pathology Centers, Research Institutes, Others), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
The Human body is a host of a variety of microbial flora. One among them is staphylococcus aureus, a gram-positive bacterium, which is most commonly found on the skin as well as in the nasal passage of human. Two major types of MRSA infections are observed, namely, hospital-acquired MRSA infection, and community-acquired MRSA infection. Majority of people are reported to have hospital-acquired MRSA infection due to the lack of hygiene & sanitation in the hospitals.
Growing incidences of MRSA infection globally and an increase in demand for the effective diagnostic techniques for the detection of MRSA infection are likely to upsurge the growth of MRSA testing market during the forecast period. In July 2017, F. Hoffmann-La Roche Ltd announced the launch of Cobas MRSA/SA, a test for detection of MRSA to be used in Cobas Liat System, further augmenting the global MRSA testing market.
To gain extensive insights into the market, Request for Customization
The growth in the global MRSA testing market is driven by increase in prevalence of hospital-acquired MRSA infection and growing developments in molecular-based techniques for the diagnosis of MRSA infection. In addition, growing investments in R&D by many players are likely to boost the growth of MRSA testing market during the forecast period.
However, high sensitivity of primers used during molecular diagnostic test is likely to hamper the growth of the global MRSA testing market during the forecast period.
Key Players Covered
Some of the major companies of the global MRSA testing market are Abbott, Hain Lifescience GmbH, 3M, Alifax Holding S.p.A., Creative Diagnostics, ZeptoMetrix Corporation, Cepheid, Abacus Diagnostica Oy, Diatherix Eurofins, LLC, Puritan Medical Products, Luminex Corporation among others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Test Type | · Molecular Diagnostic Tests · Immunodiagnostic Tests |
By End User | · Hospitals · Diagnostic & Pathology Centers · Research Institutes · Others |
By Geography | · North America (U.S. and Canada) · Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) · Latin America (Brazil, Mexico, and Rest of Latin America) · Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa) |
Growing applications of PCR in detecting mec A gene during MRSA testing and generating fast and accurate results are certain factors likely to anticipate the growth of molecular diagnostic tests during the forecast period.
Key Insights
- Epidemiology Analysis of MRSA Infections
- Overview of Technological Advances in MRSA Testing
- Pricing analysis of MRSA Tests Kits
- Key Industry Developments-Mergers, Acquisitions and Partnerships
Regional Analysis
The global MRSA testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the market during the forecasting year owing to growing awareness about the MRSA infection and growing developments in diagnostic techniques for MRSA infections. Additionally, growing investments by many key players in the research domain for the development of an effective diagnostic methods are likely to fuel the growth of MRSA testing market during the forecast period. MRSA testing market is likely to upsurge at significant rate in the Asia Pacific region owing to the growing patient population and increase in the demand for the minimally invasive diagnostic methods.
Key Industry Developments
- In July 2017, F. Hoffmann-La Roche Ltd announced the launch of Cobas MRSA/SA, a test for detection of MRSA to be used in Cobas Liat System.
- In October 2017, Abbott acquired Alere, as a result Alere became a subsidiary of Abbott and inclusion of all the point of care diagnostic kits and other products into Abbott’s product portfolio.
- In March 2016, Cepheid announced the commercial launch of Xpert MRSA NxG, a molecular-based diagnostic test for MRSA outside the U.S. market. The assay received CE-IVD status from the European Directive on in-vitro diagnostic medical devices
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
